Close Menu

NEW YORK – Agilent Technologies reported after the close of the market on Wednesday that its third quarter revenues rose 6 percent year over year, thanks largely to an 11 percent increase in revenues for its diagnostics and genomics business.

For the three months ended July 31, the firm said revenues rose to $1.27 billion from $1.20 billion in Q3 2018, beating the average Wall Street estimate of $1.24 billion. The company said core revenues also grew 6 percent in Q3.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.